Ergami Endoscopy

Executive Summary

Ergami Endoscopy is a San Jose-based medical device company developing a low-cost robotic colonoscope insertion solution designed to improve efficiency in gastroenterology procedures. Founded in 2019, the company addresses key pain points in colonoscopy: patient discomfort requiring sedation, low procedure throughput, and high rates of repetitive strain injuries among endoscopists and nurses. By automating the insertion phase, Ergami’s technology aims to reduce procedure time, minimize the need for sedation, and lower the physical burden on clinicians, thereby expanding access to colorectal cancer screening. While the company is at an early stage with no disclosed funding or regulatory milestones, its value proposition aligns with growing healthcare demands for cost-effective, minimally invasive solutions. If successful, Ergami could disrupt the traditional colonoscopy market by offering a scalable robotic platform that improves outcomes for both patients and providers. However, the lack of public clinical data or regulatory progress introduces significant uncertainty, and the company faces competition from established players like Medtronic and Auris Health, as well as emerging robotic endoscopy startups. Early-stage validation and strategic partnerships will be critical to advancing its technology toward commercialization.

Upcoming Catalysts (preview)

• Q2 2026Completion of first-in-human clinical study40% success
• Q4 2026Series A funding announcement50% success
• Q3 2026FDA 510(k) pre-submission meeting60% success